Paratek Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PARATEK PHARMS INC, and what generic alternatives to PARATEK PHARMS INC drugs are available?
PARATEK PHARMS INC has two approved drugs.
There are nine US patents protecting PARATEK PHARMS INC drugs.
There are two hundred and twenty-six patent family members on PARATEK PHARMS INC drugs in forty countries.
Summary for Paratek Pharms Inc
International Patents: | 226 |
US Patents: | 9 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 2 |
Drugs and US Patents for Paratek Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 10,383,884 | ⤷ Sign Up | ⤷ Sign Up | ||||
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 9,314,475 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | 9,724,358 | ⤷ Sign Up | ⤷ Sign Up | ||||
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 8,383,610 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Paratek Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | 7,326,696 | ⤷ Sign Up |
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | 7,326,696 | ⤷ Sign Up |
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | 9,365,500 | ⤷ Sign Up |
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | 9,365,500 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Paratek Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2836448 | ⤷ Sign Up |
Australia | 2005201623 | ⤷ Sign Up |
Japan | 2019196408 | ⤷ Sign Up |
Russian Federation | 2010152758 | ⤷ Sign Up |
Turkey | 201806893 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.